secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001493152-26-010584
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity case study shows CyPath Lung avoided invasive biopsy in high-risk nodule patient
--------------------------------------------------------------------------------

- 71-year-old former smoker with multiple lung nodules received CyPath Lung 'Unlikely Malignancy' result.
- Physician delayed invasive biopsy based on test result; follow-up CT showed nodules resolved or stable.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy in clinical study for nodules <20mm.
- Case study underscores noninvasive test's potential to reduce patient anxiety and lower healthcare costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226010584/0001493152-26-010584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226010584/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-010584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer